NOV 25, 2019 10:40 AM PST

eRapid: molecular diagnostic power in the palm of your hand

WRITTEN BY: Tara Fernandez

We’ve heard lofty biotech promises in the news of being able to diagnose diseases from a single drop of blood. Yet, diagnostic procedures for the majority of diseases still require lab-based techniques run by trained experts.

Scientists at the Wyss Institute for Biologically Inspired Engineering at Harvard University believe their new handheld electrochemical device, called “eRapid”, is capable of performing where other attempts at portable diagnostic devices have fallen short.

eRAPID: a Platform for Portable Diagnostics from Wyss Institute on Vimeo.

In the latest issue of Nature Nanotechnology, researchers Jonathan Sabaté del Río and colleagues describe a highly sensitive and inexpensive device that uses nanomaterial-coated sensors to pick up traces of disease biomarkers in biological samples.

The problem with existing technologies, such as glucometers used to quantify glucose levels in diabetics’ blood, is that over time, biological material from the sample can start to coat the sensors, rendering them inactive.

One way to impede this process, known as “biofouling”, is to coat sensors with various antifouling materials. However, this approach has proven to be an uphill battle for manufacturers of diagnostic devices, due to issues with consistency.

To tackle this challenge, the Wyss Institute engineers used a porous matrix of negatively-charged proteins as a coating, linked to the electrochemical sensors. This nanomaterial coating acted as a filter to keep positively-charged proteins in the blood from binding to the electrodes and blocking their action.

The difference this made to eRapid’s performance was impressive. Without the coating, sensors exposed to blood samples fizzled out in their ability to conduct signals within a day. On the other hand, coated sensors retained more than 90 percent of their sensitivity despite being immersed in a blood sample for a month.

Further testing revealed eRapid was capable of detecting diagnostic biomarkers with remarkable sensitivity: sensing up to a trillionth of a gram of these molecules within a single milliliter of blood.

What does the future hold for these next-generation diagnostic devices? By stacking multiple sensors in a single device, the inventors foresee eRapid becoming a widely-used portable, low-cost platform for clinical diagnostics and environmental testing alongside other applications. According to the authors, we can expect to see this potentially life-saving technology used everywhere from emergency situations to routine home care.

 

Sources: Harvard News, Nature Nanotechnology.

 

Photo credit: Wyss Institute at Harvard University

About the Author
  • Tara Fernandez has a PhD in Cell Biology and has spent over a decade uncovering the molecular basis of diseases ranging from skin cancer to obesity and diabetes. She currently works on developing and marketing disruptive new technologies in the biotechnology industry. Her areas of interest include innovation in molecular diagnostics, cell therapies, and immunology. She actively participates in various science communication and public engagement initiatives to promote STEM in the community.
You May Also Like
APR 15, 2021
Clinical & Molecular DX
A Portable Ebola Detector, 1000x More Sensitive Than Lab-Based Tests
APR 15, 2021
A Portable Ebola Detector, 1000x More Sensitive Than Lab-Based Tests
Duke University scientists have created a highly sensitive Ebola virus portable diagnostic device, 1000 times more sensi ...
APR 29, 2021
Clinical & Molecular DX
Can We Diagnose Disease Based on How "Sticky" Cells Are?
APR 29, 2021
Can We Diagnose Disease Based on How "Sticky" Cells Are?
How “sticky” cells are, or their viscosity, holds a wealth of information about their health and functionali ...
MAY 06, 2021
Clinical & Molecular DX
Sweat Sensor Can Tell If a Storm's Coming
MAY 06, 2021
Sweat Sensor Can Tell If a Storm's Coming
A surge of pro-inflammatory cytokines, intense, and sustained inflammation leading to organ damage and a high risk of de ...
JUN 08, 2021
Genetics & Genomics
Primers and Probes to Assay for SARS-CoV-2 Variants in Research Samples
JUN 08, 2021
Primers and Probes to Assay for SARS-CoV-2 Variants in Research Samples
Today, many scientists are investigating SARS-CoV-2 variants in their research projects. In order to facilitate screenin ...
AUG 19, 2021
Cancer
Vitamin D Reduces Risk of Early-Onset Colorectal Cancer
AUG 19, 2021
Vitamin D Reduces Risk of Early-Onset Colorectal Cancer
Colorectal cancer (CRC) is the third most diagnosed type of cancer in both men and women in the United States and CRC in ...
SEP 14, 2021
Clinical & Molecular DX
HIV Self-Test App Proves Promising
SEP 14, 2021
HIV Self-Test App Proves Promising
A new app allows users to self-test for HIV, which has proven to help positive patients get access to medical care and c ...
Loading Comments...